This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
MabVax Therapeutics Holdings, Inc.
Drug Names(s): TLK199 Oral, ezatiostat HCl
Description: BioMedTracker has a separate Drug Profile for the IV formulation of ezatiostat HCl. Please also see Telintra (IV).
Telik is developing a tablet formulation of Telintra. Telintra is a small molecule product candidate designed to stimulate the production of blood cells in the bone marrow. Telintra utilizes Telik's TRAP (Target-Related Affinity Profiling) technology. Telintra inhibits the enzymatic activity of glutathione S-transferase P1-1 (GST P1-1), an enzyme which displays antiapoptotic activity and is also involved in the cellular resistance to anticancer drugs. Inhibition of this enzyme, in animals, augments white blood cell production.
Telik and MabVax
In May 2014, Telik and MabVax have entered into a definitive merger agreement. Under the terms of the merger agreement, MabVax will merge with a wholly-owned subsidiary of Telik in an all-stock transaction.
Telintra (Oral) News
Additional information available to subscribers only: